Multitarget Enzyme Inhibition and Anticancer Potential of 3‐Substituted Indole Derivatives Supported by Molecular Docking Studies
Biotechnology and Applied Biochemistry · 2026
DOI: 10.1002/bab.70166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2026. Verfasst von Adnan Cetin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Education, Van Yuzuncu Yil University, Van, Türkiye. Hauptthemen laut MEDLINE: Indoles, Molecular Docking Simulation, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
The enzymes and anticancer properties of disubstituted indole, indole‐imidazole, and indole‐pyrazole derivatives were determined. These building blocks are based on a privileged 3‐substituted indole scaffold that, in turn, has been used to explore potential effects for the enzymes and cancer cells. Inhibition studies for acetylcholinesterase (AChE), glutathione S ‐transferase (GST), alpha‐amylase (α‐Amy), and alpha‐glucosidase (α‐Gly) were conducted. IC 50 values for the 3‐substituted indoles were identified as follows: AChE, 3.329 ± 0.975 to 5.544 ± 0.380 µM; GST, 2.228 ± 0.407 to 6.026 ± 1.100 µM; α‐Gly, 3.380 ± 0.616 to 5.330 ± 1.024 µM; and α‐Amy, 3.397 ± 0.472 to 5.173 ± 0.682 µM. Indole derivatives that exhibited strong enzyme inhibition were investigated for their cytotoxic effects on hepatocellular carcinoma (HepG2) and glioblastoma (U‐87) cell lines at 24 and 48 h. Overall, it was found that some indole derivatives showed IC 50 values comparable to those of the standard drug, and throughout the process, some indole derivatives exhibited good IC 50 values, indicating good activity and low cytotoxic effects. The most active compounds were identified as compound 15 against GST (IC 50 = 2.228 ± 0.407 µM), compounds 1 and 16 against AChE (IC 50 = 3.329 ± 0.975 and 3.349 ± 0.845 µM), compounds 4 and 14 in HepG2 cells (IC 50 = 33.13 and 36.71 µM at 48 h), and compounds 12 and 17 in U‐87 cells (IC 50 = 38.43 and 47.53 µM at 48 h). These indole‐based derivatives are also subjected to a structure–activity relationship (SAR) study by the molecular docking method. Most indole derivatives showed enzyme inhibition results similar to, but below, those of the standard drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Education, Van Yuzuncu Yil University, Van, Türkiye.
- Department of Medical Services and Techniques, Health Services Vocational School, Iğdır University, Iğdır, Türkiye.
- Department of Basic Sciences, Faculty of Dentistry, Iğdır University, Iğdır, Türkiye.
- Department of Basic Medical Science, Medical of Faculty, Nakhchivan State University, Nakhchivan, Azerbaijan.
- Department of Bioactive Products, Faculty of Chemistry, Adam Mickiewicz University, Poznań, Poland.
- Department of Biochemistry, Postgraduate Education Institute, Iğdır University, Iğdır, Türkiye.
ORCID-Profile: Adnan Cetin, Fikret Türkan, Karolina Babijczuk
Zitieren
APA
Cetin, A., Oguz, E., Türkan, F., Babijczuk, K., Berdzik, N., Kurgan, C., & Jasiewicz, B. (2026). Multitarget Enzyme Inhibition and Anticancer Potential of 3‐Substituted Indole Derivatives Supported by Molecular Docking Studies. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.70166
Vancouver
Cetin A, Oguz E, Türkan F, Babijczuk K, Berdzik N, Kurgan C, et al. Multitarget Enzyme Inhibition and Anticancer Potential of 3‐Substituted Indole Derivatives Supported by Molecular Docking Studies. Biotechnology and Applied Biochemistry. 2026. doi:10.1002/bab.70166
BibTeX
@article{Cetin2026,
author = {Cetin, Adnan and Oguz, Ercan and Türkan, Fikret and Babijczuk, Karolina and Berdzik, Natalia and Kurgan, Ceylan and Jasiewicz, Beata},
title = {Multitarget Enzyme Inhibition and Anticancer Potential of 3‐Substituted Indole Derivatives Supported by Molecular Docking Studies},
journal = {Biotechnology and Applied Biochemistry},
year = {2026},
doi = {10.1002/bab.70166}
}
EUVIMED